Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 16:17:100295.
doi: 10.1016/j.lrr.2022.100295. eCollection 2022.

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Abdul Muqtadir Abbasi  1 , Mohammad Usman Shaikh  2 , Natasha Ali  2 , Maria Khan  3 , Salman Muhammad Soomar  1
Affiliations

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Abdul Muqtadir Abbasi et al. Leuk Res Rep. .

Abstract

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Keywords: Complete resposne; Eltrombopag; Immune thrombocytopenia; Platelet response; Severe aplastic anemia.

PubMed Disclaimer

Conflict of interest statement

The authors do not declare any relevant conflicts of interest.

Figures

Fig. 1
Fig. 1
Treatment response to ELT in acquired idiopathic aplastic anemia.
Fig. 2
Fig. 2
Treatment response to ELT in immune thrombocytopenia.
See this image and copyright information in PMC

References

    1. Luzzatto L., Risitano A.M. Advances in understanding the pathogenesis of acquired aplastic anaemia. 2018;182(6):758–776. - PubMed
    1. Killick S.B., Bown N., Cavenagh J., Dokal I., Foukaneli T., Hill A., et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br. J. Haematol. 2016;172(2):187–207. - PubMed
    1. Tichelli A., Schrezenmeier H., Socié G., Marsh J., Bacigalupo A., Dührsen U., et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA working party of the European group for blood and marrow transplantation. Blood. 2011;117(17):4434–4441. - PubMed
    1. Kao S.Y., Xu W., Brandwein J.M., Lipton J.H., Messner H.A., Minden M.D., et al. Outcomes of older patients (>or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br. J. Haematol. 2008;143(5):738–743. - PubMed
    1. Neunert C., Noroozi N., Norman G., Buchanan G.R., Goy J., Nazi I., et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J. Thromb. Haemost. 2015;13(3):457–464. - PMC - PubMed

LinkOut - more resources